Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Chr. Hansen Holding A/S
  6. News
  7. Summary
    CHR   DK0060227585


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chr. Hansen Holding A/S : Full-year report - Statement of results 2019/20

10/08/2020 | 02:03am EDT

Company Announcement No. 23/2020

CEO Mauricio Graber says: “2019/20 was a defining and extremely eventful year for Chr. Hansen. We launched our new 2025 Strategy to become a focused bioscience company and to grow a better world, naturally. We made three acquisitions over a short period of time – HSO Health Care, UAS Laboratories and, most recently, Jennewein – and made an agreement to divest Natural Colors. We are convinced that the long-term value creation from the changes in the portfolio is very attractive, and the changes will be clearly positive to EBITDA margin in the coming year, but will also give a slight short-term negative EBIT margin impact.

On top of all of that, everyone has had to manage through a pandemic which has posed unique challenges. We ended the year with 5% organic growth for the group, well within the guidance we provided at the beginning of the year. Organic growth accelerated in Q4, driven by Health & Nutrition which delivered impressive 18% growth. We also delivered on the earnings side and came in at almost 30% EBIT margin for the full year, and at 34.3% in Q4. Our free cash flow also developed strongly, but this was partly due to capex investments that were delayed during the second half of the year due to COVID-19.

Our three strategic lighthouses – bioprotection, plant health and Bacthera – have progressed well during the year, and we launched a fourth lighthouse, fermented plant bases, at the Capital Markets Day in August 2020, and a fifth lighthouse, human milk oligosaccharides, was announced in September 2020 in connection with the acquisition of Jennewein.

We have a cautious outlook for 2020/21, given the uncertainties that COVID-19 still creates, and it will also be a year where we focus on integrating the acquired businesses and making solid progress on our strategic agenda. We expect an organic growth rate of 5-8%, in line with our long-term ambition, with the highest contribution from Health & Nutrition. We expect an EBIT margin before special items of 27-28%, given the headwinds from currencies, a normalization of the cost base, and the slight headwind from the portfolio changes. At the same time, we remain firmly committed to our long-term ambition of delivering underlying EBIT margin expansion by 2025.”

Chr. Hansen will present the results at a conference call today at 10:00am CEST (9:00am GMT). Dial-in information and a slide deck are available beforehand on https://www.chr-hansen.com/en/investors

Full announcement attached.

For further information please contact:
Martin Riise, Head of Investor Relations, Tel: +45 5339 2250
Annika Stern, Investor Relations Officer, Tel: +45 2399 2382
Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384

About Chr. Hansen

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, cleaner labels and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose –  To grow a better world. Naturally. – is at the heart of everything we do.


  • Chr. Hansen Company Announcement Q4 2019_20
  • Chr. Hansen Annual Report 2019_20
  • Chr. Hansen Corporate Governance Statement 2019_20
  • Chr. Hansen Remuneration Report 2019_20
  • Chr. Hansen Sustainability Data Sheet 2019_20

© OMX, source OMX

All news about CHR. HANSEN HOLDING A/S
05/31CHR HANSEN A/Sá : . Hansen JV With Lonza Obtains Manufacturing License In Denmar..
05/31CHR HANSEN A/Sá : Bacthera receives manufacturing licenses in Switzerland and De..
05/31CHR HANSEN A/Sá : . Hansen launches global science-based online platform on prob..
05/18CHR. HANSEN HOLDING A/S : Infrequent or one-off capital gain payment
05/17CHR HANSEN A/Sá : Extraordinary dividend
05/12CHR HANSEN A/Sá : . Hansen and Nestlé settle court case about Human Milk Oligosa..
05/11CHR HANSEN A/Sá : Sustainability roadshow presentation (May 2021)
05/11CHR HANSEN A/Sá : . Hansen launches VEGA™ Culture Kit specifically develop..
04/28CHR HANSEN A/Sá : . Hansen launches the next generation of FreshQ« food cultures..
04/28CHR HANSEN A/Sá : . Hansen launches the next generation of FreshQ« food cultures..
More news
Sales 2021 1 075 M 1 275 M 1 275 M
Net income 2021 868 M 1 030 M 1 030 M
Net Debt 2021 812 M 963 M 963 M
P/E ratio 2021 11,7x
Yield 2021 2,34%
Capitalization 10 165 M 12 061 M 12 055 M
EV / Sales 2021 10,2x
EV / Sales 2022 9,48x
Nbr of Employees 3 286
Free-Float 77,9%
Duration : Period :
Chr. Hansen Holding A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHR. HANSEN HOLDING A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Average target price 75,74 €
Last Close Price 77,16 €
Spread / Highest target 13,2%
Spread / Average Target -1,84%
Spread / Lowest Target -14,6%
EPS Revisions
Managers and Directors
Mauricio Graber President & Chief Executive Officer
Lise Skaarup Mortensen Chief Financial Officer & Executive Vice President
Dominique Reiniche Chairman
Thomas Schńfer Chief Scientific Officer & Executive VP
Winnie Hojvang BŘgel VP-Compliance & Corporate Communications
Sector and Competitors